Assessment of SOX11 expression in routine lymphoma tissue sections: Characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma

American Journal of Surgical Pathology

Volumn 38, Issue 1, 2014, Pages 86-93

  Soldini, Davide ^a,d   Valera, Alexandra ^a   Solé, Carla ^b   Palomero, Jara ^b   Amador, Virginia ^b   Martin Subero, José Ignacio ^b,c   Ribera Cortada, Inmaculada ^a   Royo, Cristina ^b   Salaverria, Itziar ^b   Beà, Sílvia ^b   Gonzalvo, Elena ^a   Johannesson, Henrik ^e   Herrera, Mileyka ^a   Colomo, Lluís ^a,b,c   Martinez, Antonio ^a,b,c   Campo, Elias ^a,b,c  

^a Hospital Clinic   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e AlbaNova University Center   (Sweden)

Author keywords

mantle cell lymphoma; monoclonal antibody; qRT PCR; SOX11

Indexed keywords

CCND1 PROTEIN, HUMAN; CYCLIN D1; DIAGNOSTIC AGENT; MESSENGER RNA; MONOCLONAL ANTIBODY; SOX11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ARTICLE; CHEMISTRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MANTLE CELL LYMPHOMA; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, MANTLE-CELL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOXC TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84891623527     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182a43996     Document Type: Article

References (32)

1. Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253-2261.
3. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315-4321.
4. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555-1562.
5. Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111:800-805.
6. Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica. 2009;94:1563-1568.
7. Chen YH, Gao J, Fan G, et al. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol. 2010;23:105-112.
8. Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26:1895-1898.
9. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408-1418.
10. Kiefer JC. Back to basics: Sox genes. Dev Dyn. 2007;236:2356-2366.
11. Weigle B, Ebner R, Temme A, et al. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep. 2005;13:139-144.
12. Lee CJ, Appleby VJ, Orme AT, et al. Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol. 2002;57: 201-214.
13. van de WM, Oosterwegel M, van NK, et al. Sox-4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes. EMBO J. 1993;12:3847-3854.
14. Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature. 1996;380:711-714.
15. Higuchi T, Nakayama T, Arao T, et al. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Blood. 2013;121:3640-3649.
16. Zeng W, Fu K, Quintanilla-Fend L, et al. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012;36:214-219.
17. Nordstro?m L, Andreasson U, Jerkeman M, et al. Expanded clinical and experimental use of SOX11-using a monoclonal antibody. BMC Cancer. 2012;12:269.
18. Vegliante MC, Palomero J, Perez-Galan P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121:2175-2185.
19. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686-1694.
20. Vegliante MC, Royo C, Palomero J, et al. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS One. 2011;6:e21382.
21. Amador V, Ge S, Santamaria PG, et al. APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell. 2007;27:462-473.
22. Pan X, Li H, Zhang P, et al. Ubc9 interacts with SOX4 and represses its transcriptional activity. Biochem Biophys Res Commun. 2006;344: 727-734.
23. Gill G. SUMO changes Sox for developmental diversity. Mol Cell. 2005;20:495-496.
24. Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology. 2012;29:685-693.
25. Dy P, Penzo-Mendez A, Wang H, et al. The three SoxC proteins-Sox4, Sox11 and Sox12-exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res. 2008;36: 3101-3117.
26. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
27. Huppmann AR, Leung AA, Jaffe ES, et al. SOX11 is a marker of follicular dendritic cell neoplasms. Mod Pathol. 2011;24:302A.
28. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012;97:270-278.
29. Cao X, Fan L, Fang C, et al. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases. Med Oncol. 2012;29:1190-1196.
30. Troussard X, vet-Loiseau H, Macro M, et al. Cyclin D1 expression in patients with multiple myeloma. Hematol J. 2000;1:181-185.
31. Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in Cyclin D1-negative mantle cell lymphoma. Blood. 2012;121:1394-1402.
32. Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol. 2008;143:248-252.